Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

por Wang, Yan-Yu, Yang, Xu, Wang, Yun-Chao, Long, Jun-Yu, Sun, Hui-Shan, Li, Yi-Ran, Xun, Zi-Yu, Zhang, Nan, Xue, Jing-Nan, Ning, Cong, Zhang, Jun-Wei, Zhu, Cheng-Pei, Zhang, Long-Hao, Yang, Xiao-Bo, Zhao, Hai-Tao
Publicado 2023